STAAR Surgical (STAA) – Research Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for STAAR Surgical (NASDAQ: STAA):

• 8/4/2026 – STAAR Surgical was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/4/2026 – STAAR Surgical had its “outperform” rating reaffirmed by Wedbush. They now have a $40.00 price target on the stock.
• 8/1/2026 – STAAR Surgical was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/28/2026 – STAAR Surgical is now covered by UBS Group AG. They set a “sell” rating and a $20.00 price target on the stock.
• 7/22/2026 – STAAR Surgical had its “outperform” rating reaffirmed by Wedbush. They now have a $40.00 price target on the stock.
• 7/16/2026 – STAAR Surgical had its “outperform” rating reaffirmed by Wedbush. They now have a $40.00 price target on the stock.
• 7/5/2026 – STAAR Surgical was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/27/2026 – STAAR Surgical was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/25/2026 – STAAR Surgical was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.